Exagen News

Exagen Inc Board Reshuffle and New Class I Director Appointment

TipRanksApr 26 20:42

Exagen: Brian Birk, Ebetuel Pallares, Wendy Johnson to Step Down From Board, Effective June 10 >XGN

Exagen: Brian Birk, Ebetuel Pallares, Wendy Johnson to Step Down From Board, Effective June 10 >XGN

Dow JonesApr 26 20:32

Exagen: Scott Kahn Joining Board >XGN

Exagen: Scott Kahn Joining Board >XGN

Dow JonesApr 26 20:32

Exagen Reducing Size of Board to Seven Directors From Nine >XGN

Exagen Reducing Size of Board to Seven Directors From Nine >XGN

Dow JonesApr 26 20:31

Press Release: Exagen Inc. Announces Changes to the Board of Directors

Exagen Inc. Announces Changes to the Board of Directors CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today annou

Dow JonesApr 26 20:30

The Exagen Inc. (NASDAQ:XGN) Annual Results Are Out And Analysts Have Published New Forecasts

As you might know, Exagen Inc. (NASDAQ:XGN) just kicked off its latest yearly results with some very strong numbers. It looks like a positive result overall, with revenues of US$53m beating forec

Simply Wall StMar 23 02:55

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report

Yahoo FinanceMar 21 18:25

Exagen Inc.'s (NASDAQ:XGN) 28% Dip In Price Shows Sentiment Is Matching Revenues

Exagen Inc. (NASDAQ:XGN) shareholders won't be pleased to see that the share price has had a very rough month, dropping 28% and undoing the prior period's positive performance. The drop over the la

Simply Wall StMar 20 18:19

Exagen Full Year 2023 Earnings: Beats Expectations

Yahoo FinanceMar 20 18:16

Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives

TipRanksMar 20 17:56

Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 19 21:37

Exagen's Challenge: Strengthening Financial Controls to Restore Confidence and Secure Growth

TipRanksMar 19 14:00

Exagen's Strong Q4 Performance and Positive Outlook Justify Buy Rating

TipRanksMar 19 07:05

Earnings Call Summary | Exagen(XGN.US) Q4 2023 Earnings Conference

The following is a summary of the Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript:Financial Performance:Exagen reported a record full-year revenue of $52.5 million for 2023, a 15% increase over 202

Futu NewsMar 19 01:30 · Conference Call

Exagen Reports Q4 Results

Seeking AlphaMar 18 23:27

Canopy Growth, Outlook Therapeutics, Immuneering Among Healthcare Movers

Seeking AlphaMar 18 22:00

Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, Vs. Street Est of $11.6M

08:45 AM EDT, 03/18/2024 (MT Newswires) -- Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M

MT NewswiresMar 18 20:45

Exagen Expects Q1 FY2024 Revenue Of $13M-$13.5M Versus Consensus Of $11.49M, The Company Says Existing Cash And Cash Equivalents Of $36.5M Will Be Adequate To Meet Anticipated Cash Requirements Into 2026

Exagen Expects Q1 FY2024 Revenue Of $13M-$13.5M Versus Consensus Of $11.49M, The Company Says Existing Cash And Cash Equivalents Of $36.5M Will Be Adequate To Meet Anticipated Cash Requirements Into 2

BenzingaMar 18 20:09

Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) Estimate, Sales $13.77M Beat $11.56M Estimate

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.91 percent. This is a 62.65 percent increase over losses of $(0.83) per sh

BenzingaMar 18 20:03

Exagen 4Q Rev $13.8M >XGN

Exagen 4Q Rev $13.8M >XGN

Dow JonesMar 18 20:00